Biora Therapeutics Inc (BIOR) Peer Comparison
$0.69
$0.00
(0.01%)
As on 08-Jul-2022 09:30EST
Market cap
$163 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
163 | 3,154 | 2,635 | 1,853 | 870 |
Revenue ($ Mln) |
1 | 442 | 549 | 130 | 387 |
Net Profit ($ Mln) |
-155.94 | -198.39 | 17.88 | -46.09 | 24.10 |
Net Margin (%) |
376.16 | -44.91 | 3.26 | -35.42 | 6.23 |
RoE (%) |
-- | -32.38 | 1.43 | -8.11 | 8.60 |
Price to Earnings |
-- | -- | 151.60 | -- | 38.41 |
Price-To-Book |
-- | 5.60 | 1.95 | 3.23 | 3.05 |
Income Statement ($ Mln)
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1.00 | 144.31 | 356.13 | 7.46 | 198.87 |
|
Cost of Revenue
|
0.00 | 52.24 | 28.79 | 85.73 | 21.14 |
|
Gross Profit
|
1.25 | 92.07 | 327.34 | -78.28 | 177.73 |
|
Operating Expenses
|
68.76 | 792.14 | 684.45 | 115.06 | 158.72 |
|
Operating Profit (EBIT)
|
-84.84 | -700.06 | -357.10 | -109.10 | 19.01 |
|
Other Income
|
-42.45 | -- | -- | -- | -- |
|
Profit before Tax
|
-126.30 | -703.41 | -155.12 | -99.63 | 23.08 |
|
Provision for Tax
|
-0.96 | 1.06 | 11.92 | -0.82 | 7.08 |
|
Profit after Tax (Net Income)
|
-155.94 | -704.47 | -194.65 | -98.81 | 16.00 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-155.94 | -704.47 | -194.65 | -98.81 | 13.49 |
Liabilities ($ Mln)
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-96.11 | 1,379.96 | 986.89 | 581.40 | 218.71 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
132.62 | 37.10 | 21.49 | 69.05 | 178.70 |
|
Current Liabilities
|
40.58 | 192.90 | 311.66 | 94.27 | 53.02 |
|
Total Liabilities
|
108.84 | 1,609.96 | 1,372.66 | 744.72 | 450.44 |
Assets ($ Mln)
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
16.96 | 109.08 | 160.59 | 596.49 | 167.64 |
|
Current Assets
|
60.15 | 1,500.88 | 1,212.08 | 148.23 | 282.80 |
|
Total Assets
|
108.84 | 1,609.96 | 1,372.66 | 744.72 | 450.44 |
|
Total Debt*
|
0.00 | 15.54 | 38.98 | 105.50 | 183.39 |
|
Net Current Assets
|
0.00 | 1,307.98 | 900.42 | 53.95 | 178.82 |
Cashflow ($ Mln)
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-167.49 | -549.23 | -204.22 | -106.68 | 37.84 |
|
Cash Flow from Investing Activities
|
-1.24 | 249.96 | -306.32 | -1.65 | -21.31 |
|
Cash from Financing Activities
|
166.83 | 820.20 | 650.03 | 114.47 | -27.95 |
|
Net Cash Inflow / Outflow
|
-3.68 | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
3,501.69 | -54.54 | -25.13 | -14.80 | 4.67 |
|
ROE (%)
|
257.76 | -55.27 | -26.46 | -17.48 | 8.67 |
|
ROA (%)
|
-90.97 | -48.46 | -18.57 | -13.37 | 4.03 |
|
EBIT Margin (%)
|
-15,251.46 | -- | -- | -- | -- |
|
Net Margin (%)
|
376.16 | -488.16 | -54.66 | -1,325.25 | 8.04 |
|
Cash Profit Margin (%)
|
-0.02 | -- | -- | -- | -- |
Growth Ratios
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-98.47 | 1.95 | 0.56 | -0.77 | -0.06 |
|
EBIT Growth (%)
|
24.02 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
33.19 | -161.98 | -54.55 | -26.78 | -57.62 |
|
EPS Growth (%)
|
0.62 | -1.40 | -0.31 | -0.07 | -0.61 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.40 | -85.15 | -30.86 | -4.90 | 39.19 |
|
Price / Book Value
|
-4.08 | 43.47 | 6.09 | 0.83 | 2.87 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-1.11 | -84.98 | -34.16 | -5.35 | 12.15 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.32 | 0.01 | 0.04 | 0.18 | 0.84 |
|
Short term debt to equity ratio
|
-0.06 | 0.00 | 0.03 | 0.10 | 0.02 |
|
Current Ratio
|
1.48 | 7.78 | 3.89 | 1.57 | 5.33 |
|
Quick Ratio
|
1.48 | 7.68 | 3.77 | 1.57 | 4.75 |
|
Interest Coverage
|
-10.33 | -207.75 | -261.03 | -8.30 | 4.17 |
Operating Efficiency Ratios
| Biora Therapeutics Inc (BIOR) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
82.11 | 37.98 | 41.48 | 61.56 | 15.73 |
|
Asset Turnover
|
0.01 | 0.10 | 0.34 | 0.01 | 0.50 |
|
Receivable days
|
1,952.93 | 75.90 | 100.31 | 144.81 | 46.40 |
|
Inventory Days
|
-- | 112.20 | 352.24 | -1.07 | 417.05 |
|
Payable days
|
-- | 660.05 | 461.79 | 94.94 | 169.67 |
|
Cash Conversion Cycle
|
-- | -471.95 | -9.25 | 48.79 | 293.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
